news that dish has made an unsolicited offer for clearwire. it is down by 2%. sprint issues a statement saying that dish's offer is highly conditional and it believes its offer is superior ongoing story to watch in tomorrow's session. time for the final trade. mike? >> clearwire looked like a big pill for sprint. i'd be a seller of dish on this. >> keith? >> buy boeing. >> guy? >> mr. mcgregor has me thinking. broadcom tomorrow. >> karen? >> gardner denver. gdi. >> j.j.? >> i like goldman sachs. >> all right, i am melissa lee. see you tomorrow, 9:00 a.m. for "squawk on the street." the ceo of gm. you can catch more "fast money" begin at 5:00. happy birthday to us, our sixth anniversary here at the nasdaq market site. all right, next hour, "mad money" with jim cramer starts right now.

i'm jim cramer. welcome to my world. you need to get in the game. firms are going to go out of business and he's nuts. they're nuts. they know nothing. i always like to say there's a bull market somewhere. "mad money," you can't afford to miss it. hey, i'm cramer. welcome to "mad money." welcome to cramerica. other people want to make friends. just trying to save you a little money. my job is not just to entertain you but educate and teach. call me 1-800-743-cnbc. don't you just hate reality? boo! don't you hate it when you know the numbers are too high or the world is simply not yet in a place where you can be confident that things are okay? don't you hate that members of the federal reserve think that we have reached a great place so it is time to stop helping the econo

economy. don't you hate that washington doesn't care what place that we are in at all. don't you hate that karma. >> house of pleasure. >> house of pain. >> down 55 points today. nasdaq declining 42.3%. you know i hate all of these things. what do you do? no, you look for themes. that is why i'm a big believer of themes. all week i plan to plan out the themes of 2013 that you can fall back on when the dow falls. they are dominated by anxiety. i expect the market to go down in the near future. but look, i think it is too high right now and maybe it comes in.

but i don't want you to fear that decline. no opportunity, use it as a chance to buy the sectors that can bounce back harder and faster than anything else. i want you to be ready. i need you to take profits in your winners. we have had so many winners since the kwleyear began. winners and losers have gone up so far in 2013. keep winners, trim losers. last night i told you about bankers. autos could be natural places to sing the blues. i love the one we are having in ford. you begin positions. you won 100 shares, i buy 25 tomorrow. and you get the picture. tonight i'm giving you two more themes for 2013. ones that i think you can count

on when everyone else is fleeing from the building. the first? the building itself. housing. yeah. hey listen, i think 2013 is going to be another year when new and unsold homes will drive gigantic returns throughout the stock market returns that are going to be let's say consistent which is what i know you really want. you know a lot of different people get a lot of different opinion s to housing. but you know what? i don't care. i'm not an economics professor. i don't care about the statistics. i'm a stock pit and all i care about is what the strength in housing means. not for what is going to happen with taxes. i'm talking about stocks for

individual companies and for them, it is nothing short of amazing. buy buy buy. >> house of pleasure. >> the home builders, i know all of those stocks have had magnificent runs in 2012 but i don't think they are over. the bad news is home builders have moved so high, it is worth waiting for some scare. some federal reserve pop off. downgrading the stocks before i would do any buy buy buy and when they pull back i think you go for toll brothers and then there are the housing related retailers. home depot. i think here you want to go with the multi year term at pier one. especially since the multi year

strategy is just kicking in. plenty to choose from here. owens corning. home and security for kitchen and bath, sherman williams for paint and rubbermaid and stanley, black and decker and mohawk for carpets and gpsum board. i'm told they need that bad in new jersey. louisiana pacific and w ax weyerhouser. you will be bidding with my charitable trust. i'm always buying below the market. don't forget some of these ansillary plays. the cable companies. when you buy a new home you hook it up. probably will make you money.

i work for one. or the materials companies. makes ago gates for new roads. berkshire hathaway. of course one of the nation's hearthest railroad a e largest railroads. the housing rally continues? can the housing rally continue? how many times have we heard that question? how many times have we condition told it is a matter of time before the fed turns off the juice he is going to keep the money going until we reach the goal of 6.5 unemployment. we have been building homes at a rate of 1.5 million a year in this country. but we dropped to building 400,000 a couple of years ago. talk about unsustainable. that is crazy. of course the bears, man, they

are everywhere aren't they? the bears, wake up will you? the bears, they told us it didn't matter. the prices couldn't rise. because of the shadow inventory. you know how they do those things? you know what? we have worked through that. the continuing rally of the bank stocks telling you that the fears about under water home owners are not going to be realized. and there are still affordable buys and rents are out-of-control in this country. so much better to buy if we can. multiple years of housing strength ahead. and second theme for tonight off the beaten track. insurance. boy, insurance boring. i love boring. the insurance group performer, whether it be genworth, i wrote

them a check for life insurance. travelers, allstate, paying you a lot of money, but you paid me back when the roof went. i think 2013 could be no different. in fact, it could be better. i used to downgrade this terrific group all the time. allowing insurance rates to go up. that has been the number one thing. even after last year's gains. so well behind the market. most importantly, the asset side of the insurance business. it is coming back to life with a vengean vengeance. as housing increases in value the paper is coming back. to me, aig is the best way to play it. everything that is bad is now good. which is why my buy is now good.

he has your back here. he is the ceo. given my earlier theme. again, you might want to go with war reiren buffet and berkshire hathaway. here is the bottom line. two themes that are the bottom line. find one that you like. as the politicians and their fear mongers create all through 2013:roy in california. >> yeah, jim, this is roy an active investor required and back in february of 2007 you were speaking at a college and you were really recommending very highly the sears holding company and it was being run by a fellow that you had complete confidence in eddie lambert. at the time we purchased the stock and it paid $185 for it.

i'm still holding onto it after four years. should i hold on to that or take my bath i appreciate your comments and i do enjoy your program daily. >> i change my mind too. the answer is that i turned on sears. it wasn't easy. but, the numbers turned down. housing turned down. i had a good gain and turned it to a loss for some and sold the stock and never looked back and i'm still not looking back. i guess the answer is there is so many stocks out there. i got it right, wrong, right, but what is important is there is no place for you. we are looking for themes that can last. two hot sectors that look like they are ready to sore

long-term. find names that you like and stick around we have a lot more to come. >> coming up, best in biotech. it is the largest health care conference of the year. and tonight cramer is shaping the je next generation of breakthroughs. will this year hold similar suck tess? plus jim's got an expolluticlush a company changing the way drugs are developed. just ahead. don't miss a second of "mad money." follow at jim cramer on twitter. send jim and e-mail to "mad money." or give us a call. at 1-800-743-cnbc. miss something?

head to madmoney.cnbc d.comadmo. tonight, top contender fortre fortressry secretary. is he only experioienced at pol? the kudlow report on cnbc. ♪ [ male announcer ] don't just reject convention. drown it out. introducing the all-new 2013 lexus ls f sport. an entirely new pursuit. nothing. are you stealing our daughter's school supplies and taking them to work?

no, i was just looking for my stapler and my... this thing. i save money by using fedex ground and buy my own supplies. that's a great idea. i'm going to go... we got clients in today. [ male announcer ] save on ground shipping at fedex office. [ male announcer ] save on ground shipping i've always had to keep my eye on her... but, i didn't always watch out for myself. with so much noise about health care... i tuned it all out. with unitedhealthcare, i get information that matters... my individual health profile. not random statistics. they even reward me for addressing my health risks. so i'm doing fine... but she's still going to give me a heart attack. we're more than 78,000 people looking out for more than 70 million americans. that's health in numbers. unitedhealthcare.

when the bar is set too high. it becomes difficult for investors. case in point, regn today. here is a stock that has been up 179%. that is right in the last 12 months. thanks to the strength of ilea. we have been with the company every step of the way. no one else has believe me. we recommended the stock back in 2005. a few months after the show began. and it is up 30% since the last time that we spoke in august. it is one of the reasons that we encouraged you to speculate. the company has a fabulous drug one that continues to take the market share plus last fall the only competition to this drug came under a cloud of worries

that a distribu ter may have contaminated it's contents. but when you have been roaring like this company has, just this morning the company presented at the big jp morgan conference and while the sales came in better than the expectations, it wasn't enough to beat the whisper number, it was one point down four points down $5.83. is this a case where wall street has caught up with the street? let's check in with dr. len schleifer to get a better sense of how the company is doing. welcome back. >> great to be here. >> i want to congratulate you on your performance and that

science magazine named you one of the best pharmaceutical companies in the world. >> we are lucky. my partner since we opened the labs nearly 25 years ago, actually we started the company. today is our birthday. 25 years ago today we actually signed the first papers that started the company. but when we opened the labs in 1989, my partner, we believed that the key to the business was to do good science and then get individual scientists and treat them well and let them run and they would get across the finish line like they have. i thought the sales were amazing. did they expect more because one of your competitors was caught up in a pharmacy compounding problem?

is that what people expected because of the problem with your competitor? >> yeah, it is hard to know what drives people exactly expect and why they expect it. but there was a problem with compounding pharmacies. people had fungal meningitis and died. but that put a question mark around a lot of drugs and people thought that the market leader actually, this drug avacin which is used off label but made by compounding pharmacies but shifted to the branding drugs, i don't think that was a reasonable expectation, we had a strong quarter, we are at a run rate that is well over $1 billion. we are expected to have 50% growth. so this franchise is going well. perhaps we didn'tp get everything everybody was whispering about but we are

still thrilled. >> which is going to be bigger your anti-cholesterol drug or ilea? >> you are a bit uncanny. you did discover us when we were a $5 stock. you anticipated that ilea would be a bigger drug than we thought it would be. we did $838 million last year and you started talking about the cholesterol drug when nobody else was interested. it could be very big. and ilea with built to grow in the united states. it is still something that we can bank on. cholesterol lowering is still needed by tens of millions of people. together we are hoping that we can lead this way forward to bring a new class of cholesterol

lowering drugs which could be bigger but we will have to see. >> i have been trying to take every single statin in the book. i had a thing called trigger finger recently. i cannot type when i'm taking them. i'm begging to be on your trials. all the new research says that everybody in the world should be on statins but not everyone can tolerate them. >> there are millions of people who probably should be on them but can't tolerate them. certainly people do have muscle aches and various pains and it is a big problem coming up with lowering cholesterol. we hope one of the ways that it will be used in one of the ways that we can tolerate statins.

if you are on a statin and you can't get to the goal that you should get to we can still lower it. this is a power full class of drugs. we have to make sure that we meet the requirements but a lot of people are excited about it. you mortgaged your house to get the first few drugs through. now you have you are going to have billions of cash. you even say in your conference call we don't know how to do with that cash. you have more than you need. >> right. you know, i have spent unless you think we are an overnight success. we have been at this for 25 years. for the last 24 years, we have been looking for cash. we have been scratching every thing that can get cash.

and now, you expect us to be experts in deploying that cash. we will figure it out. but if we focus on our research. trying to get things that will make a difference frept in pati lives we will be in good shape. >> congratulations being the ceo of the number one performing stock and thank you for choose g ing "mad money" to be the first interview. you are are a good man. >> thank you we love being here. >> 25th birthday for r aegenero. let's hope you get another price break like you had this morning. what a give stay with cramer. >> coming up, cash injection? if you are bullish on biotech

listen up. cramer spotted the potential for a sizable move in one of the largest health care companies around. don't miss the reveal of this play in tonight's edition of off the charts. with the spark cash card from capital one, sven gets great rewards for his small business! how does this thing work? oh, i like it! [ garth ] sven's small business earns 2% cash back on every purchase, every day! woo-hoo!!! so that's ten security gators, right? put them on my spark card! why settle for less? testing hot tar... great businesses deserve great rewards!

[ male announcer ] the spark business card from capital one. choose unlimited rewards with 2% cash back or double miles on every purchase, every day! what's in your wallet? here's your invoice.

every tuesday when you go on

twitter, this is everybody's favorite segment. i try to teach you about some things. the technicians use to get a read on where things are going. all of this might seem like the charts are beyond comprehension. sometimes the charts can be dead simple. straight forward. right. that is what tonight is about. tonight we are going off the chart with tim collins and my colleague at thestreet.com. and what he says is the best chart out there. pfizer. the big pharma company that has been doing a lot of good things. bringing out value. he said it reminds him of

monsanto. back when he loved what he saw on the chart on july 23rd. man what i call. since then the stock has been roaring. collins nailed this one. it is also not like the companies that seem to have regular meaningful breakthroughs. those are science factories that seem to do nothing but produce amazing drugs that go down in what seems like 60 seconds. pretty csolid company. when he looks at the daily chart he sees some things that makes him think that phizer could be ready to run. they are trying to a certain things that seem to make it over and over again into an up stock or down stock and pfizer has

made the bullish pattern one that col llins is very excited. it has made an inverse head and shoulders formation. it is called that because it looks like an upside down head between two shoulders. not at all because it can be an upside down bottle of shampoo that are shaped like a reverse head and shoulder. pfizer made the left shoulder and declined and then in november the stock bottomed to form the head. and then the eye there. give it some hair. that is what the smart good looking guys have. anyway, and last month, in december we caught a rally and a pull back which created the right shoulder. when you see a right side up. that is a reliable indicator

that a stock could be about to get hammered. now the key with this pattern is the neck line. the line that connects to the highs with the two shoulders, it tells someone like collins, the neckline, it would be like this. i like to use the head and shoulders because it is dumb and stupid and funny. and it crossed over that level. last week. if this pattern holds true, the stock should rally. come on man, this is pfizer. within a month, collins will give this run six month to play out. it goes much higher, that is pretty darn good. in other words he thinks you give this some time. it is a healthy flow of support.

a flow of support of $2460 and you got two more support levels in the $23 range. we like that. we got a dollar down and $2.50 here. wait a second. there is just not a lot of risk versus the reward. it is not just the price action. i want you to look at the bottom of the chart. this is called the triple exponential moving after rage. this is the tool to detect the trend before they happen. collins likes the tricks not because they are for kids, not because they are serials, he likes them because it can be good at predicting rallies. when the black line crosses over the red line. that is known what is called as a bullish crossover. the tricks is making one of the

bullish crossover here. right now. the last three times we caught a bullish crossover. the end result was to sustain the move higher. look at these lines, okay? they markhe last three positive crossovers. sometimes rallying quite hard. however, it is important to hear, one month after these began. after the initial move higher, collins thinks you could have another chance. you see it drop back down. it is a chance to get back in at the same level. check out pfizer's weekly chart. as you can see at the beginning of last year. so go back to the beginning. side ways action, okay? and that is consolidation.

ility it laid the ground work. ever since the stock broke out. it is running higher in the bullish chennel. just as we saw at the beginning of 201. all right? the stock has been building a base. pfizer broke out above the 2550. if it closes above that level again, it is a nice looking chart. what else? look at the accumulation distribution line at the bottom. this is a volume based independent k indicator. you can see, when it goes down. long periods of sideways movement. we had another period. so if that is in turn followed by another move higher. collins can see it push the

stock up of $27.86. beyond that, collins can see the stock go to $30. that is a possibility for pfizer before the end of the year. that is a 47% gain from where the stock is now. remember, everything is risk reward. maybe $2.80. that is nirvana. that is my view. you know i'm a fan of pfizer. i like the gilliads. now this stock was up 15%. last week i told you i thought i could repeat that. that is exactly what collins is predicting too. it is as boring as it gets. pfizer lets you sleep soundly at night. it puts you to sleep. the bottom line, it is rare that you get a safe, boring rare stock like fipfizer that has a

smoking hot chart. not like what brett musberger had in the stands last night. for me, that is one more reason why pfizer is a bu buy bu buy. let's go to phil in south dak a dakota. >> booyah cramer. my question is astroxeneca. >> it is not bad. but if you went conservative growth i'm going to send you to pfizer. let's go to renee in california. >> booyah jim. >> tattoo removal stock i bought some a year ago. it has doubled in value and five years ago you called it best of breed. >> you know, earlier we had a

call about someone that said you liked sears five years ago. i'm not a big fan of tattoos as i would tell my daughters. but a tattoo removal play? hey, in an merge say they may be the way to go. the big pharma dinosauris more like a velociraptor. i've always been a fan of tricks. don't move the lightening round is next. ♪

[ male announcer ] how do you make 70,000 trades a second... ♪ reach one customer at a time? ♪ or help doctors turn billions of bytes

of shared information... ♪ into a fifth anniversary of remission? ♪ whatever your business challenge, dell has the technology and services to help you solve it.

it is time for the lightening round. >> let's start with joe. >> i have a lot of esc. >> well done. >> and i want to lighten up more

now. should i wait? >> i don't know. maybe you should wait, sir. here is the problem. these guys sell, they didn't like verify it. they were talking about other things. i own utilities for diffdends, that means sell, sell, sell. let's go to justin in illinois. >> i have a bear's booyah for you. >> i will give you a lovy smith was robbed booyah. >> ah for earnings as of late. do you think it is a good time to buy? >> i don't know. i will do work. let's go to milton, ohio. >> jim, a big booyah to you. >> nice. >> what is your recommendation on lowes? >> look, i don't need to be in

lowes. there are others that are better. charleses in maryland. >> how you doing? >> booyah, got a question with key corp why are we getting beat up so bad? >> there are guys that think that this drug that they have is not worth the paper that it is printed on. there are mistakes that i have made. press corp is a mistake. this is a hard group. and that was a speculation. i did not nail it correctly. and i'm walking away from it. and i reiterate that i got it wrong. i get them wrong. it just haps. >> let's go to john in pennsylvania. john. >> jim, thanks for taking my call. i'm interested in your short and long-term views. >> i have been against coal.

>> every dog has it's day. >> that stock can go up ten percent before i would sell it. >> jaim, thank you for your insight over the jeeryears. >> i do like this. remember, like this more than i did in the last few weeks. because of the change in the yield curve because of loan demand getting stronger. and that ladies and gentlemen is the conclusion of the lightening round. >> the lightening round is sponsored by td ameritrade. >> coming up. beating the market's performance in 2012. but can it continue to climb higher. cramer speaks to the ceo on the

heels of their invest eor presentation next. from busser tf before opening a restaurant specializing in fish and game from the great northwest. he'll start investing early, he'll find some good people to help guide him, and he'll set money aside from his first day of work to his last, which isn't rocket science. it's just common sense. from td ameritrade.

it's just common sense. living with moderate to semeans living with pain.is it could also mean living with joint damage. help relieve the pain and stop the damage with humira, adalimumab. for many adults with moderate to severe ra, humira is clinically proven to help relieve pain and stop joint damage. so you can treat more than just the pain. humira can lower your ability to fight infections, including tuberculosis. serious, sometimes fatal events, such as infections, lymphoma, or other types of cancer, have happened. blood, liver and nervous system problems, serious allergic reactions, and new or worsening heart failure have occurred. before starting humira, your doctor should test you for tb. ask your doctor if you live in or have been to a region where certain fungal infections are common. tell your doctor if you have had tb, hepatitis b, are prone to infections or have symptoms such as fever, fatigue, cough, or sores. you should not start humira if you have any kind of infection. ask your rheumatologist about humira, to help relieve pain and stop further joint damage before they stop you.

after another down day, i want to circle back to a biotech story. wow, i'm talking about biogen, binb. a classic stock that is the kind of thing that you should think about buying. how robust is it? last week we found out that the company announced disappointing data for a drug it had been working on. this is a drug that a lot of people had been looking forward to. the reason? this drug is small potatoes. now there is no cure for ms. it attacks the central nervous system. we have drugs that can keep it at bay. right now it has two of them on the market.

newer more effective drug that has a higher risk of side effects. and biogen is working on a third drug, bg 12 one that can be taken orally instead of just injected. it would appeal to a broader population. this could be a $2.4 billion drug in sales by 2016. big deal. plus it has a major hemophelia group. so we have plenty to look forward to. let's talk to dr. george the o ceo, welcome to "mad money." >> thank you. >> pleasure to be here. >> doctor, let me ask you this, when i look at the prospects for

bg12, i see maybe the ultimate pill for this disease and i wonder whether it is so great for patients that it will hurt your other franchise. >> that is a good question. we don't think that it will. we see other segments in the market. we see diverse populations and we are very happy now to have three very good products on the market now that will appeal to broad ksegments to the population. >> i think no doubt this is going to be a gigantic drug. i'm trying to think who would take an injection versus a pill. >> some patients are on avanex that are being well treated. their disease is well controlled and there is no reason for them

to switch. as you said, it provides a high level of therapy to patients and they are happy with that drug. we have 30% of the ms market. that means we don't have 70% of the market and we intend to get some of that 70%. >> i stood by you guys when this scare occurred. i was confident that you would come up with something that would indicate when for who there could be a problem. you guys are far along in being able to isolate anyone who this could have a dangerous side effect right? >> yes, we are. over the years we determined a number of risk factors who made patients less likely to suffer the side effect s and there are patients that are at low risks for the disease. >> and what does it mean for you

guys? >> the avanix pen is an injecter. the patient doesn't see the needle. it doesn't hurt. so it is a convenience issue for patients and in that first line class of therapies where it competes? it is a big issue and we have seen a lot of patienten th enthm and we have seen them gaining share as a result. >> we see that you may be close to the break out drug. and that is something i know a hideous disease that only one company has dominated. >> you think this might be a better mouse trap in that too. >> we are proud of factor 8 and 9. look hemopheliacs have to inject themselves to keep themselves

from having unwanted bleeds. that is a major improvement on what is a major you know pretreatment burden for these patients. we think they can provide a service to those patients. >> one last one. i know you had to discontinue development. what is so what is so difficult about trying to beat this disease? >> yeah, it has been a difficult disease. it is a devastating disease for the patients who have it. this was a particularly disappointing failure for us. we have had four results. three were positive and this one was negative. we would have liked to bring something to these patients. we are doing more work now to understand the genetics of the disease and i'm hopeful that the increased understanding will

allow us to bring forward a dra drug that will provide a benefit of alk. >> thank you so much for coming on "mad money." >> thank you, jim, appreciate it. >> that is doctor george scangos. he is the ceo of one of our favorite stocks. think about what they are doing. i believe they will be best in class. these are gigantic diseases and they have the best stuff. stay with cramer.

at a dry cleaner, we replaced people with a machine. what? customers didn't like it. so why do banks do it? hello? hello?! if your bank doesn't let you talk to a real person 24/7, you need an ally. hello? ally bank. money needs an ally.

gold? sure we finally found some buyers today. there are a million reasons why it has been going down. the dollar is stronger and chaos in europe is stronger. i have to tell you, everyone of those things is big. using the proxy is going from $184 down to $160 right now. and during that period we had plenty of chaos oversees and we saw the circumstances that are being credited for gold's weakness. i stand in defense of owning gold. i think that we were having the long awaited pullback.

because gold took off and is coming in, in such a way that we would be all over the selloff. no matter which gold company i listen to, the fouinding costs continue to go higher. you have to expect the love affair with the precious metal at diminished and the inflation scare in china, the demand in united states off the charts expecting competition. let's face it. we are in a phase of monetary policy all over the globe. there are countries that are trying to re-ignite growth and a line of nations trying to change the nations.

buying 80% of the bonds because we refuse to make cuts in spending. despite interesting change in sentiment, so you got plenty of reasons to want gold as your default currency. 12 years of higher prices a pretty long run. finally, the failure to find a new huge source of gold. every time i think it happens, i'm disappointed to get out of the ground without much effort or cost. gold, i hope it comes down more. so i can recommend it hard to get gold into everyone's portfolio. stick with cramer. next, top contender fortressry secretary. is he the right person to lead

our economic policy? larry sets the debate in motion the kudlow report next on cnbc. surgery was successful, but he will be in a cast until it is fully healed, possibly several months. so, if the duck isn't able to work, how will he pay for his living expenses? aflac. like his rent and car payments? aflac. what about gas and groceries? aflac. cell phone? aflac, but i doubt he'll be using his phone for quite a while cause like i said, he has a fractured beak. [ male announcer ] send the aflac duck a get-well card at getwellduck.com.

office superstore ink retailer in america. now get $6 back in staples rewards for every ink cartridge you recycle when you spend $50 on hp ink. staples. that was easy. nothing. are you stealing our daughter's school supplies and taking them to work? no, i was just looking for my stapler and my... this thing. i save money by using fedex ground and buy my own supplies. that's a great idea. i'm going to go... we got clients in today.